Rodolfo Lanocita
- Hepatology top 1%
- Surgery top 10%
- Pulmonary and Respiratory Medicine top 10%
- Epidemiology top 10%
- Radiology, Nuclear Medicine and Imaging top 5%
- Co-authors
- Carlo SpreaficoAlfonso MarchianòVincenzo MazzaferroCarlo MorosiSherrie BhooriCarlo SpositoMarco MaccauroRaffaele Romito
- Topics
- Hepatocellular Carcinoma Treatment and Prognosis (16 papers)Renal cell carcinoma treatment (8 papers)Central Venous Catheters and Hemodialysis (5 papers)
- Partner nations
- ItalyUnited StatesMalaysia
In The Last Decade
Rodolfo Lanocita
49 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Hepatology 785
- Surgery 409
- Pulmonary and Respiratory Medicine 340
- Epidemiology 328
- Radiology, Nuclear Medicine and Imaging 246
Countries citing papers authored by Rodolfo Lanocita
This map shows the geographic impact of Rodolfo Lanocita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rodolfo Lanocita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rodolfo Lanocita more than expected).
Fields of papers citing papers by Rodolfo Lanocita
This network shows the impact of papers produced by Rodolfo Lanocita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rodolfo Lanocita. The network helps show where Rodolfo Lanocita may publish in the future.
Co-authorship network of co-authors of Rodolfo Lanocita
This figure shows the co-authorship network connecting the top 25 collaborators of Rodolfo Lanocita. A scholar is included among the top collaborators of Rodolfo Lanocita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rodolfo Lanocita. Rodolfo Lanocita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 3 | |
| 4 | 0 | |
| 5 | 2 | |
| 6 | 1 | |
| 7 | 103 | |
| 8 | 54 | |
| 9 | 19 | |
| 10 | 38 | |
| 11 | 2 | |
| 12 | 6 | |
| 13 | 5 | |
| 14 | 22 | |
| 15 | 5 | |
| 16 | 106 | |
| 17 | 15 | |
| 18 | 50 | |
| 19 | The Italian experience with SH U 508 A (Levovist) in breast disease. | 5 |
| 20 | 77 |
About Rodolfo Lanocita
Rodolfo Lanocita is a scholar working on Hepatology, Emergency Medical Services and Urology, having authored 50 papers that have together received 1.4k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Renal cell carcinoma treatment (8 papers) and Central Venous Catheters and Hemodialysis (5 papers). The work is most often cited by research in Hepatology (785 citations), Radiation (97 citations) and Radiology, Nuclear Medicine and Imaging (246 citations). Rodolfo Lanocita has collaborated with scholars based in Italy, United States and Malaysia. Frequent co-authors include Carlo Spreafico, Alfonso Marchianò, Vincenzo Mazzaferro, Carlo Morosi, Sherrie Bhoori, Carlo Sposito, Marco Maccauro, Raffaele Romito, Claudio Chiesa and Enrico Civelli. Their work appears in journals such as Journal of Clinical Oncology, Blood and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.